<DOC>
	<DOCNO>NCT02208713</DOCNO>
	<brief_summary>Facioscapulohumeral Dystrophy Autosomal dominant inherit dystrophy prevalence 1:20,000 third common dystrophy dystrophinopathies myotonic dystrophy . The symptom include : Pain , facial weakness , scapular fixator , humeral , truncal , pelvic girdle lower-extremity weakness , High frequency hearing loss , Retinal telangiectasia . The exist treatment effective , cell therapy new hope improve patient ' quality life . Therefore , We design clinical trial evaluate safety feasibility stem cell transplantation .</brief_summary>
	<brief_title>Intramuscular Transplantation Muscle Derived Stem Cell Adipose Derived Mesenchymal Stem Cells Patients With Facioscapulohumeral Dystrophy ( FSHD )</brief_title>
	<detailed_description>In study , select 15 patient FSHD base eligibility criterion . All patient underwent physical examination , laboratory evaluation , EMG-NCV , muscle sonography muscle MRI . Then , sample patient 's muscle take Biceps Femoralis isolate culture MDSC . The AD-MSC prepared Royan Adipose Tissue Bank . The patient admit general hospital , cell suspension inject biceps , triceps trapezoid muscle neurologist . After transplantation , patient observation 5 hour discharge side effect happen . All patient follow 1,2,4,6 12 month cell injection .</detailed_description>
	<criteria>1 . Age : 1850 2 . Both gender 3 . Weakness face muscle 4 . FSHD phenotype positive 5 . Genetic Test confirmation FSHD 1 . Co morbidity : Heart &amp; respiratory disease , malignancy , rheumatologic disorder 2 . Progressive form disease 3 . Not able sign consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>FSHD muscle derive stem cell adipose derive mesenchymal stem cell intramuscular injection</keyword>
</DOC>